A041702

Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age)
Contact phone
517.364.2835
Principal investigator
Gordan Srkalovic MD, PhD
Trial Category
Cancer
Trial SubCategory
Hematology
Webform